Anandamide VS CBD: ʻO wai ka mea ʻoi aku ka maikaʻi no kou olakino? ʻO nā mea āpau āu e ʻike ai e pili ana iā lākou!

Pehea e holo ai ʻo Anandamide (AEA)

Loaʻa ka Anandamide (AEA) mai ka non-oxidative metabolism o ka eicosatetraenoic acid. ʻO Anandamide (AEA) kahi mea waena lipid a me nā hana ma ke ʻano he ligand endogenous o nā CB1 receptor a hoʻololi i kāna huakaʻi uku. He neurotransmitter koʻikoʻi ia i loko o ka ʻōnaehana endocannabinoid, i kapa ʻia ma hope o Cannabis. Kōkua ia i ka hoʻoponopono ʻana i ke kahe o nā ʻōnaehana neurochemical e mālama pono i kou kino a me kou noʻonoʻo. ʻIke ʻia he ʻano like ke ʻano Anandamide me tetrahydrocannabinol (THC), ka mea psychotic nui o Cannabis. Pēlā ʻo Anandamide e loli ai i ke ʻano simulate i ka mea i ʻike nui ʻia ʻo Cannabis kiʻekiʻe.

Hana maoli ʻia ia i loko o kā mākou kino e like me ke aʻo ʻana o ka lolo e ka hopena condensation i nā neurons. ʻO ka hopena condensation e kāohi ʻia e ka sodium calcium a me ka cyclic monophosphate adenosine e hana ʻia ma waena o ka acid arachidonic a me ka ethanolamine.

Hoʻonui ʻo Anandamide i ka hauʻoli ma o ka launa pū ʻana me nā mea loaʻa cannabinoid i loko o ka ʻōnaehana hopohopo a me nā ʻōiwi, CB1 a me CB2. Hoʻokumu nā mea loaʻa CB1 i ka hana moto (neʻe) a me ka hoʻohui ʻana, ka noʻonoʻo ʻana, ka makemake, ka hoʻomanaʻo pōkole, ka ʻike ʻeha, a me ka palekana. I ka manawa like, hoʻokūkū nā mea loaʻa CB2 i nā mea nui e like me ka Liver, Gut, kidney, Pancreas, nāʻaʻaʻa Adipose, nā ʻiwi iwi, ka iwi, ka maka, nā tumors, ka ʻōnaehana, nā ʻōnaehana Immune, nā ʻōnaehana Respiratory, ka ʻili, ka ʻōnaehana Nervous Central, a me ka ʻōnaehana Cardiovascular. .

I loko o ko mākou kino, N-arachidonoylethanolamine e haki i loko o ka fatty acid amide hydrolase (FAAH) enzyme a hana i ka acid arachidonic a me ka ethanolamine. Inā hiki ke hoʻolōʻihi ʻia ka hana a FAAH'sFAAH, hiki iā mākou ke ʻohi i nā pono o Anandamide'sAnandamide no kahi wā lōʻihi.

Pehea e holo ai ʻo Cannabidiol (CBD)?

Aia i loko o ko mākou kino kahi ʻōnaehana kūikawā i kapa ʻia ka ʻōnaehana endocannabinoid kuleana no nā loli physiological. Hoʻokumu ke kino i nā endocannabinoids ma kāna iho. ʻO ka endocannabinoid nā neurotransmitters e hoʻopaʻa ai i nā mea loaʻa cannabinoid.

Aia he ʻelua mau mea lawe ʻai cannabinoid; Nā mea loaʻa CB1 a me CB2. Loaʻa nā mea loaʻa CB1 ma loko o ke kino a ma ka lolo hoʻi. Kaohi lākou i kou naʻau, manaʻo, neʻe, makemake, hoʻomanaʻo, a me ka noʻonoʻo.

Loaʻa nā mea loaʻa CB 2 ma ka ʻaoʻao ʻē aʻe i ka ʻōnaehana pale a hoʻoulu i ka mumū a me ka ʻeha.

ʻOiai paʻa paʻa ʻo THC i nā mea loaʻa CB1, ʻaʻole paʻa paʻa ʻo CBD i nā mea loaʻa akā hoʻonāukiuki i ke kino e hana i nā endocannabinoids hou aʻe. Hiki i ka CBD ke hoʻopaʻa a hoʻohana paha i nā mea loaʻa ʻē aʻe e like me ka receptor serotonin, vanilloid, a me nā PPAR [peroxisome proliferator-activated activated] nā mea loaʻa. Hana ʻo CBD ma ke ʻano he antagonist i nā GPR55-orephan receptor.

Hoʻopili ʻo CBD i ka reseptor serotonin i hoʻopili ʻia i ka hopohopo, hiamoe, ʻike i ka ʻeha, makemake, nausea, a me ka luaʻi.

Hoʻopili pū ʻo CBD i ka receptor vanilloid i ʻike ʻia e hoʻopōkā i ka ʻeha, ka wela, a me ka mahana o ke kino.

Hana ʻo CBD ma ke ʻano he antagonist i ka receptor GPR55 e hōʻike pinepine ʻia i nā ʻano maʻi ʻaʻai like ʻole.

Hana pū ʻo Cannabidiol ma ke ʻano he agena anti-inflammatory. E hakakā a hoʻomāmā paha i ka mumū.

Loaʻa iā Cannabidiol nā waiwai antioxidant e hiki ai iā ia ke hoʻopau i nā radical manuahi e pili pinepine ʻia me nā maʻi degenerative.

H Hoʻonui i ka hiki i ka lolo a me ka hoʻomanaʻo

ʻO ka hoʻonui ʻana i kou hiki i ka hoʻomanaʻo ʻana ka hana nui Loaʻa maikaʻi ʻo Anandamide (AEA). Kōkua pū ia iā ʻoe e lilo i mea hana hou aʻe ma o ka hana ʻana i ka ʻike i nā manaʻo hou. Ua hōʻike kahi noiʻi i nāʻiole i ka hoʻomaikaʻi nui ʻana i ka hana o ka lolo. Pēlā inā makemake ʻoe e hoʻomaikaʻi i kāu mākau anamanaʻo, nā mākau hana, a hana maikaʻi paha i kāu mau aʻo ʻana, ʻo Anandamide ka hopena kūpono.

③ Neurogenesis

ʻO kahi ala e hoʻonui ai i kāu hana lolo ka loaʻa ʻana o nā neurons hou a i ʻole nā ​​pūnaewele lolo ma o Neurogenesis. He ʻoiaʻiʻo kēia, ke neʻe nei ʻoe i 40 a i ʻole ua hala ma mua o ka makahiki. Kōkua ʻo Anandamide (AEA) ma Neurogenesis.

Eia kekahi, ʻo nā pae kiʻekiʻe o nā Anandamide i loko o ke kino o ke kanaka e hoʻopau i nā makaʻu o nā maʻi neurodegenerative e like me ka maʻi ʻo Perkinson'serkerkinson, a pēlā aku. ke kino, a pēlā aku. Anandamide (AEA) kōkua i nā mākua makua e hauʻoli i ko lākou ola hoʻomaha me ka hopohopo ʻole e pili ana i nā pilikia olakino.

⑤ Nā anti-Cancer waiwai

Loaʻa ka Anandamide (AEA) i nā waiwai ant carcinogenic ma o nā hopena psychotropic. Kūʻē ʻo Anandamide (AEA) i ka ulu maʻi maʻi maʻi maʻi maʻi. He mea maikaʻi loa ia i ka maʻi ʻaʻai umauma. Ke hōʻike nei nā hoʻokolohua hiki ke lilo i pani maikaʻi no nā lāʻau maʻamau o ka maʻi ʻaʻai. Eia kekahi, ʻaʻohe ona hopena i hoʻohālikelike ʻia i nā hopena hoʻololi o ke ola o nā lāʻau ʻaʻai maʻamau. No laila i ka manawa pōkole, ʻo ka ʻae ʻia nui o Anandamide (AEA) e hōʻemi paha i ka ʻeha a nā mea maʻi maʻi maʻi i hele ai i ka wā o ka mālama ʻana.

⑦ Nā mea kōkua ʻeha

Ma ka hoʻopaʻa ʻana me CB1, Anandamide (AEA) ālai i ka lawe ʻia ʻana o nā hōʻailona ʻeha. ʻO kēia ala, Anandamide (AEA) hiki ke hoʻohana ʻia no ka hōʻeha ʻeha mau loa i nā mea maʻi e ʻeha ana i nā kūlana olakino e like me ka gout, arthritis, a sciatica paha. I nā makahiki ʻelemakule, he hoa hele mau ka ʻeha. ʻO Anandamide (AEA) kahi lāʻau i hōʻoia ʻia no ka migraines a me nā maʻi poʻo ʻeha ʻē aʻe. ʻO ka hoʻohana ʻana i nā mea kōkua Anandamide (AEA) i ka wā ʻelemakule e kōkua iā lākou e lanakila i ka ʻeha a hoʻomaikaʻi hoʻi i ko lākou ola.

⑨ E hakakā i ke kaumaha

Anandamide (AEA) hiki ke kaua aku hoʻi kaumaha. Ua hōʻoia ʻia kahi noiʻi ma nā ʻiole i kāna mau ʻano antidepressant. ʻO ke kaumaha a me nā pilikia e pili ana ke lawe nui nei i ko mākou olakino a me ke olakino ... ʻoiai i ko mākou kaiāulu. Hoʻopili pinepine i ka nikotine, ʻalekohola, hoʻohana lāʻau ʻino me ke kaumaha. ʻO nā kūlana ʻoi loa paha ke alakaʻi i ka poʻe e lawe i ko lākou ola. Hiki i ke kaumaha ke lilo i mea hōʻemi maikaʻi ʻole e hiki ai ke alakaʻi i ka poʻe i ka make. Hiki i ka Anandamide (AEA) ke lilo i hopena maikaʻi loa i kēia pilikia.

i. Black Truffles (ʻeleʻele fungi)

Aia nā Black Truffles i ka Anandamide maoli.

ii. Keahi a me nā mea kanu

Cannabis, cloves, cinnamon, black pepper, oregano, etc. hoʻomaikaʻi i nā pae Anandamide i loko o kā mākou kino. He kumu maikaʻi loa ʻo Tea o Anandamide (AEA).

hoʻokō '

Lawe ka hoʻoikaika i kahi mea maikaʻi i loko o mākou. Hoʻonui ka hoʻomaʻamaʻa i nā pae Anandamide i loko o ke kino a no laila hoʻonui i kou ʻano e hoʻoikaika ikaika. Hōʻike nā hoʻokolohua ma hope o ka hoʻoikaika kino, lilo lākou i mālie a pale i ka ʻeha. Manaʻo ʻia kēia ma muli o ka hoʻoulu ʻia ʻana e Anandamide e CB1 a me CB2'sCB2. ʻIke ʻia he 30 mau minuke o ka holo ikaika ʻana a i ʻole nā ​​aerobics e hoʻonui nui i nā pae Anandamide i loko o kā mākou kino. ʻIke ʻia nō hoʻi nā mea maʻi migraines e lawe i nā aerobics e mālama hou i ka mea like. ʻO ia ma muli o nā kiʻekiʻe o Anandamide i hana ʻia i ko lākou kino ma muli o ka hana nui.

ʻO ke kaumaha ʻO ke kaumaha

ʻO ka poʻe hiki ke kaohi i ke koʻikoʻi ke kiʻekiʻe o Anandamide i loko o lākou. Hoʻoemi ka pilikia i ka hopena o nā mea loaʻa CB1 a pēlā e hōʻemi ai i nā pae o Anandamide a, a laila, hōʻike i ka hoʻemi ʻia o ka hana cannabinoid. Pēlā e hōʻalo ai i nā hanana pilikia e hoʻomaikaʻi ai i ke ola holoʻokoʻa. ʻO kekahi o ia ʻano hopena ʻo ka noʻonoʻo. Hoʻomaikaʻi ka hoʻohui i nā pae Anandamide a me nā dopamine i loko o kā mākou kino. Mediatbodiesleads i ke kiʻekiʻe o ka oxytocin e hoʻonui hou ai i nā pae Anandamide i loko o kā mākou kino. He like ia me kahi pōʻai maikaʻi o ke ola maikaʻi. Kōkua ʻo Anandamide iā ʻoe e hoʻomālie a noʻonoʻo; hoʻonui ka noʻonoʻo ʻana i kāu pae Anandamide a kōkua iā ʻoe e hōʻoluʻolu mai ke koʻikoʻi.

Hana Anandamide (AEA)

E like me nā endocannabinoids ʻē aʻe, maikaʻi ke ana o waho o Anandamide no mākou. ʻO nā lāʻau kiʻekiʻe ke hoʻopōʻino i ko mākou kino. 1.0mg / kg. (no Kg o ke kaumaha o ke kino) kūpononā huahana o Anandamide (AEA). Akā inā ʻoe e ʻike i kekahi pilikia, pono ʻoe e nīnau koke i ke kauka. I nā makuahine hāpai a me nā makuwahine e hānai ana i ka waiū pono lākou e nīnau i kā lākou kauka ma mua o Anandamide (AEA) hoʻohana.

Nā hopena ʻaoʻao ʻo Anandamide (AEA)

He ahonui kiʻekiʻe ʻo Anandamide a me nā hopena ʻaoʻao haʻahaʻa. Hiki paha iā ʻoe ke ʻike i kekahi mau pilikia kūlohelohe e like me ka lilo ʻana o ke kaupaona, dizziness, a i ʻole ka luaʻi. I kekahi mau hihia, ʻo ka Anandamide (AEA) hoʻomalu i ka wā o ka hānai ʻana (i aʻo ʻia i nā ʻiole makua) hiki i ke kaupaona ʻana, ka hōʻiliʻili momona o ke kino, a me ke kūpaʻa o ka insulin. Hana kēia ma muli o ka hoʻonui ʻana o ka makemake e alakaʻi i ka ʻai nui.

Cannabidiol (CBD) hoʻohana

ʻO nā mea aʻe ka hoʻohana ʻia ʻana o ka cannabidiol;

● Ke mālama ʻana i ka maʻi hopu (epilepsy)

Hoʻohana ʻia ʻo Cannabidiol e mālama i ka hopu ʻana. Hiki i ka CBD ke hoʻololi i nā kaha sodium o ke aʻa nerve. ʻO kahi mea koʻikoʻi i ka epilepsy ka neʻe maʻamau o ka sodium i loko a i waho o nā hunaola. ʻO kēia ke kumu o ka lolo e kī i ke ahi e alakaʻi maʻamau i ka hopu ʻana. Ua loaʻa ʻo CBD e hōʻemi i kēia kahe maʻamau o ka sodium no laila e hōʻemi i ka hopu ʻana.

Ua ʻae ʻia kekahi mau huahana CBD e like me Epidiolex no ka mālama ʻana i nā maʻi hopu a Lennox-Gastaut Syndrome, Dravet Syndrome, a i ʻole tuber sclerosis complex. Hoʻohana pū ʻia kēia lāʻau lapaʻau me nā lāʻau anti-seizure ʻē aʻe e mālama ai i ka hopu ʻana i ka poʻe e loaʻa ana i ka maʻi Sturge-Weber, ka maʻi maʻi epilepsy e pili ana i ka maʻi febrile, a me kekahi mau maʻi kūlohelohe e hoʻopiʻi ana i ka epileptic encephalopathy.

I loko o kahi noi 2016 e pili ana i 214 mau kānaka e ʻeha nei i ka maʻi epilepsy, lawelawe ʻia ʻo CBD ma 2 a 5 mg i kēlā me kēia lā no 12 mau pule me ka hoʻohui ʻia o ka lāʻau epilepsy. Ua ʻike ʻia he ʻoi aku ka hopu ʻana o ka poʻe komo i kēlā me kēia mahina.

● Hiki ke hoʻohana ʻia i ka mālama ʻana i ka maʻi ʻaʻai

Hiki ke hoʻohana ʻia ka aila Cannabidiol e hōʻemi i nā ʻōuli e pili ana i ka maʻi ʻaʻai a me nā hopena ʻē aʻe o ka mālama ʻana i ka maʻi ʻaʻa e like me ka ʻeha, nausea, a me ka luaʻi.

I ke aʻo ʻana o 16 mau maʻi ʻaʻai e hele ana i ka chemotherapy, ua hoʻohana ʻia ʻo CBD me THC e hōʻemi i nā hopena e pili ana i ka chemotherapy e like me ka nausea a me ka luaʻi.

Ua hōʻike ʻia kahi noiʻi ʻē aʻe ua kāohi maikaʻi ʻo CBD i ka ulu ʻana o ka maʻi ʻaʻai umauma i nāʻiole.

● Hōʻike i nā pono neuroprotective

Ka hiki i ka CBD ke hoʻohuli i ka ʻōnaehana endocannabinoid a me nā ʻōnaehana hōʻailona lolo ʻē aʻe i mea maikaʻi i nā poʻe me nā maʻi neurological. Hiki i ka aila CBD ke hōʻemi i ka līlū e pili pū me nā maʻi neurodegenerative.

Ua nānā ka hapa nui o nā noiʻi i ka hoʻohana ʻana o CBD i ka mālama ʻana i nā maʻi neurological e like me ka epilepsy a me nā sclerosis he nui. Hōʻike ka noiʻi i ka hiki ke hoʻohana ʻia i ka mālama ʻana i nā maʻi ʻē aʻe e like me ka maʻi Alzheimer a me ka maʻi ʻo Parkinson.

I kahi loiloi lōʻihi o nā ʻiole i hōʻike mua ʻia i ka maʻi o Alzheimer, ua loaʻa ʻo CBD e pale aku i ka emi ʻana o ka ʻike.

● Ke mālama ʻana i ka maʻi diabetes 1

ʻAno 1 diabetes he ʻano o ka maʻi diabetic e kū i ka wā e pale ai ka ʻōnaehana pale i nā hunaola i ka pancreas, hopena kēia i ka puhū.

Ua loaʻa ʻo CBD i nā ʻano anti-inflammatory, no laila e hōʻoluʻolu paha ia i ka lī ʻana a hoʻolohi paha i ka loaʻa ʻana o ka maʻi diabetes type 1.

I ke aʻo ʻana i nā ʻiole me ka maʻi kō, ua loaʻa ʻo CBD e pale aku i nā neurons e ka pale ʻana i ka emi o ka naʻau a me ka hōʻemi ʻana i ka mumū nerve.

Nā pono ʻo Cannabidiol (CBD)

He laulā ka nui o nā pono kōkua he Cannabidiol.
Ma lalo iho nei kekahi o nā pono cannabidiol;

● Hiki ke hōʻemi i ka hopohopo a me ke kaumaha

Hiki iā Cannabidiol (CBD) ke kōkua i ka hōʻemi ʻana i ka hopohopo a me ka hoʻoliʻiliʻi ʻana i kekahi ʻano e pili ana i ka hopohopo e pili ana i nā kūlana e like me ka maʻi o ka hopohopo nui, nā maʻi panic, nā maʻi ʻōiwi, a me nā maʻi stress post-traumatic (PTSD).

I ke aʻo ʻana i nāʻiole, ʻike ʻia ka cannabidiol e hōʻike i nā hopena anti-hopohopo a me nā antidepressant.

● Hiki ke hōʻoluʻolu i ka ʻeha

Hāʻawi ʻo CBD i kahi hōʻeha ʻeha kūlohelohe ma mua o nā lāʻau lapaʻau maʻamau.

Aia i loko o kā mākou kino kahi ʻōnaehana endocannabinoid loea i kuleana no ka hoʻoponopono ʻana i ka hiamoe, ʻeha, ka puhū, a me ka pane ʻana o ka ʻōnaehana pale. Pēlā e hoʻopuka ai ke kino i nā endocannabinoids, nā neurotransmitters e hoʻopili i nā mea loaʻa cannabinoid i kāu ʻōnaehana hopohopo.

Ua hōʻike ʻia ʻo CBD i ka hopena o ka ʻōnaehana endocannabinoid a pēlā e hōʻemi ai i ka ʻeha a me ka mumū.

I ka hui pū ʻana me THC, hiki ke hoʻohana ʻia ka aila CBD e mālama i ka ʻeha e pili ana i nā ʻano like ʻole e like me nā sclerosis he nui, ka maʻi pākī, ʻehaʻeha sciatic, a me nā ʻeha o ke kuamoʻo.

I ke aʻo ʻana i ka poʻe e ʻeha nei i ka rheumatoid arthritis, CBD i hoʻohana pū ʻia me THC i loaʻa e hōʻoluʻolu nui i ka ʻeha i ka neʻe ʻana a me ka hoʻomaha a me ka maikaʻi o ka hiamoe o nā mea maʻi.

● Hiki ke hōʻemi i ka huehue

ʻO ka huehue kahi maʻi ʻili e pili i nā poʻe he nui. Ma muli paha o nā genetics, ka puhū ʻana, a me ka hana nui ʻana o ka sebum (kahi mea aila i hana ʻia e nā sebaceous glands i ka ʻili).

Hōʻike ka noiʻi e hiki i ka CBD ke kōkua i ka hōʻemi ʻana i ka huehue ma ka hana ʻana ma ke ʻano he anti-inflammatory agents a me ka hoʻēmi ʻana i ka hana sebum.

Eia kekahi laʻana, ua ʻike ʻia kahi noiʻi kanaka ua hiki i ka aila CBD ke pale aku i ka hana nui ʻole ʻana o ka sebum e nā gland sebaceous no laila he lapaʻau maikaʻi o ka huehue.

● Hiki ke kōkua i ka haʻalele ʻana i ka puhipaka a me ka haʻalele ʻana i ka lāʻau

Hiki i ka CBD ma ke ʻano he inhaler ke kōkua i ka poʻe puhipaka e hoʻohana i nā uahi ʻuʻuku a me ka hōʻemi ʻana i kā lākou hōʻalo i ka nikotine. He mea nui kēia i ke kōkua ʻana i kekahi e haʻalele i ka puhipaka.

I loko o kahi noi ma 2018 ua kaulana ʻo CBD e kōkua i ka hoʻohaʻahaʻa ʻana i ka makemake no ka paka ma hope o ka haʻalele ʻana. Ua loaʻa e kōkua i kekahi e noho nanea.

Hiki iā Cannabidiol (CBD) ke hāʻawi i nā keu pono ʻē aʻe e like me;

• Hiki ke kōkua i ka poʻe me ka hiamoe ʻole e loaʻa ka maikaʻi a me ka hiamoe pau ʻole
• Hiki iā ʻoe ke hoʻokuʻu iā ʻoe mai ka headache a i ʻole migraine,
• Hiki iā ia ke kōkua i ka hōʻemi ʻana i ka nausea,
• Hiki ke kōkua i ke kōkua i nā maʻi āpau a i ʻole ka hānō
• Hiki ke hoʻohana ʻia i ka mālama ʻana i nā kūlana māmā.

Kau ʻia ka wana aila Cannabidiol i ke ʻano o ka hoʻokele, ke kumu i manaʻo ʻia, ka makahiki, a me nā ʻano kumu ʻē aʻe. Inā makemake ʻoe e hoʻohana i ka aila cannabidiol pono ʻoe e nīnau i kāu kauka pehea e lawe ai i ka aila CBD ma mua o ka loaʻa ʻana iā ia no ka ʻōlelo aʻoaʻo ʻoihana e pili ana i ka hoʻohana kūpono a me nā mea hana. Pehea e lawe ai i ka aila CBD e kaukaʻi ʻia i ke ʻano o ka hoʻoponopono ʻana e like me;

• Lawe ʻia ka papa a me nā capsule i ka waha a i ʻole ka sublingally
• Lawe waha ʻia ka ʻaila Cbd
• ʻAila Cbd no ka noi ʻana ma ka ʻili
• Nasal sprays no ka hanu ʻana

ʻOiai he mea hou loa ka cannabidiol ʻaʻohe mea maʻamau no nā ʻano hana like ʻole. Eia naʻe, ua ʻae ka FDA i ka hoʻohana ʻana o Epidiolex, kahi o nā huahana i loaʻa i ka cannabis. Ua ʻae ʻia no ka mālama ʻana i ka epilepsy koʻikoʻi i hoʻokumu ʻia e Dravet Syndrome a i ʻole Lennox-Gastaut Syndrome.

ʻO ke ana i koi ʻia no Epidiolex penei:

• ʻO ka mahele hoʻomaka he 2.5 mg / Kg o ke kaumaha o ke kino i lawe ʻia i ʻelua mau manawa i kēlā me kēia lā, e hana ana i ka nui o nā ana o 5 mg / kg i kēlā me kēia lā.
• Ma hope o 1 pule, hoʻonui ʻia paha ka lāʻau i 5 mg / kg i ʻelua mau lā i kēlā me kēia lā, ʻo ia ka nui o 10 mg / kg i kēlā me kēia lā.